546 related articles for article (PubMed ID: 32949118)
1. Determinants of suboptimal CD4
Handoko R; Colby DJ; Kroon E; Sacdalan C; de Souza M; Pinyakorn S; Prueksakaew P; Munkong C; Ubolyam S; Akapirat S; Chiarella J; Krebs S; Sereti I; Valcour V; Paul R; Michael NL; Phanuphak N; Ananworanich J; Spudich S;
J Int AIDS Soc; 2020 Sep; 23(9):e25585. PubMed ID: 32949118
[TBL] [Abstract][Full Text] [Related]
2. Immune recovery in HIV-1 infected patients with sustained viral suppression under long-term antiretroviral therapy in Ethiopia.
Wolday D; Legesse D; Kebede Y; Siraj DS; McBride JA; Striker R
PLoS One; 2020; 15(10):e0240880. PubMed ID: 33091053
[TBL] [Abstract][Full Text] [Related]
3. Impact of CD8+ T-cell activation on CD4+ T-cell recovery and mortality in HIV-infected Ugandans initiating antiretroviral therapy.
Hunt PW; Cao HL; Muzoora C; Ssewanyana I; Bennett J; Emenyonu N; Kembabazi A; Neilands TB; Bangsberg DR; Deeks SG; Martin JN
AIDS; 2011 Nov; 25(17):2123-31. PubMed ID: 21881481
[TBL] [Abstract][Full Text] [Related]
4. Rapid CD4 decline prior to antiretroviral therapy predicts subsequent failure to reconstitute despite HIV viral suppression.
Darraj M; Shafer LA; Chan S; Kasper K; Keynan Y
J Infect Public Health; 2018; 11(2):265-269. PubMed ID: 28826735
[TBL] [Abstract][Full Text] [Related]
5. Enhanced immunovirological response in women compared to men after antiretroviral therapy initiation during acute and early HIV-1 infection: results from a longitudinal study in the French ANRS Primo cohort.
Novelli S; Delobel P; Bouchaud O; Avettand-Fenoel V; Fialaire P; Cabié A; Souala F; Raffi F; Catalan P; Weiss L; Meyer L; Goujard C
J Int AIDS Soc; 2020 Apr; 23(4):e25485. PubMed ID: 32333726
[TBL] [Abstract][Full Text] [Related]
6. Characteristics of suboptimal immune response after initiating antiretroviral therapy among people living with HIV with a pre-treatment CD4 T cell count <200 cells/mm
Han WM; Ubolyam S; Apornpong T; Kerr SJ; Hansasuta P; Gatechompol S; Maekanantawat W; Ruxrungtham K; Phanuphak P; Ananworanich J; Avihingsanon A
J Virus Erad; 2020 Sep; 6(3):100005. PubMed ID: 33251023
[TBL] [Abstract][Full Text] [Related]
7. The extent of HIV-1-related immunodeficiency and age predict the long-term CD4 T lymphocyte response to potent antiretroviral therapy.
Kaufmann GR; Bloch M; Finlayson R; Zaunders J; Smith D; Cooper DA
AIDS; 2002 Feb; 16(3):359-67. PubMed ID: 11834947
[TBL] [Abstract][Full Text] [Related]
8. Determinants of CD4+ T cell recovery during suppressive antiretroviral therapy: association of immune activation, T cell maturation markers, and cellular HIV-1 DNA.
Goicoechea M; Smith DM; Liu L; May S; Tenorio AR; Ignacio CC; Landay A; Haubrich R
J Infect Dis; 2006 Jul; 194(1):29-37. PubMed ID: 16741879
[TBL] [Abstract][Full Text] [Related]
9. HIV Reservoir Decay and CD4 Recovery Associated With High CD8 Counts in Immune Restored Patients on Long-Term ART.
Zhang LX; Jiao YM; Zhang C; Song JW; Fan X; Xu RN; Huang HH; Zhang JY; Wang LF; Zhou CB; Jin L; Shi M; Wang FS
Front Immunol; 2020; 11():1541. PubMed ID: 32793212
[No Abstract] [Full Text] [Related]
10. Factors influencing the normalization of CD4+ T-cell count, percentage and CD4+/CD8+ T-cell ratio in HIV-infected patients on long-term suppressive antiretroviral therapy.
Torti C; Prosperi M; Motta D; Digiambenedetto S; Maggiolo F; Paraninfo G; Ripamonti D; Cologni G; Fabbiani M; Caputo SL; Sighinolfi L; Ladisa N; El-Hamad I; Quiros-Roldan E; Frank I
Clin Microbiol Infect; 2012 May; 18(5):449-58. PubMed ID: 21919996
[TBL] [Abstract][Full Text] [Related]
11. Assessment of chloroquine as a modulator of immune activation to improve CD4 recovery in immune nonresponding HIV-infected patients receiving antiretroviral therapy.
Routy JP; Angel JB; Patel M; Kanagaratham C; Radzioch D; Kema I; Gilmore N; Ancuta P; Singer J; Jenabian MA
HIV Med; 2015 Jan; 16(1):48-56. PubMed ID: 24889179
[TBL] [Abstract][Full Text] [Related]
12. Influence of lifelong cumulative HIV viremia on long-term recovery of CD4+ cell count and CD4+/CD8+ ratio among patients on combination antiretroviral therapy.
Seng R; Goujard C; Krastinova E; Miailhes P; Orr S; Molina JM; Saada M; Piroth L; Rouzioux C; Meyer L;
AIDS; 2015 Mar; 29(5):595-607. PubMed ID: 25715104
[TBL] [Abstract][Full Text] [Related]
13. Effects of first-line antiretroviral therapy on the CD4/CD8 ratio and CD8 cell counts in CoRIS: a prospective multicentre cohort study.
Serrano-Villar S; Martínez-Sanz J; Ron R; Talavera-Rodríguez A; Fernández-Felix BM; Herrera S; Muriel A; Fanjul F; Portilla J; Muñoz J; Amador C; de Zárraga MA; Vivancos MJ; Moreno S;
Lancet HIV; 2020 Aug; 7(8):e565-e573. PubMed ID: 32763219
[TBL] [Abstract][Full Text] [Related]
14. Enhanced CD4+ T-cell recovery with earlier HIV-1 antiretroviral therapy.
Le T; Wright EJ; Smith DM; He W; Catano G; Okulicz JF; Young JA; Clark RA; Richman DD; Little SJ; Ahuja SK
N Engl J Med; 2013 Jan; 368(3):218-30. PubMed ID: 23323898
[TBL] [Abstract][Full Text] [Related]
15. Lower CD4+ T lymphocyte nadirs may indicate limited immune reconstitution in HIV-1 infected individuals on potent antiretroviral therapy: analysis of immunophenotypic marker results of AACTG 5067.
D'Amico R; Yang Y; Mildvan D; Evans SR; Schnizlein-Bick CT; Hafner R; Webb N; Basar M; Zackin R; Jacobson MA
J Clin Immunol; 2005 Mar; 25(2):106-15. PubMed ID: 15821887
[TBL] [Abstract][Full Text] [Related]
16. Determinants of Restoration of CD4 and CD8 Cell Counts and Their Ratio in HIV-1-Positive Individuals With Sustained Virological Suppression on Antiretroviral Therapy.
Gras L; May M; Ryder LP; Trickey A; Helleberg M; Obel N; Thiebaut R; Guest J; Gill J; Crane H; Dias Lima V; dʼArminio Monforte A; Sterling TR; Miro J; Moreno S; Stephan C; Smith C; Tate J; Shepherd L; Saag M; Rieger A; Gillor D; Cavassini M; Montero M; Ingle SM; Reiss P; Costagliola D; Wit FWNM; Sterne J; de Wolf F; Geskus R;
J Acquir Immune Defic Syndr; 2019 Mar; 80(3):292-300. PubMed ID: 30531492
[TBL] [Abstract][Full Text] [Related]
17. Discordant outcomes following failure of antiretroviral therapy are associated with substantial differences in human immunodeficiency virus-specific cellular immunity.
Price DA; Scullard G; Oxenius A; Braganza R; Beddows SA; Kazmi S; Clarke JR; Johnson GE; Weber JN; Phillips RE
J Virol; 2003 May; 77(10):6041-9. PubMed ID: 12719595
[TBL] [Abstract][Full Text] [Related]
18. The role of extended-release niacin on immune activation and neurocognition in HIV-infected patients treated with antiretroviral therapy - CTN PT006: study protocol for a randomized controlled trial.
Lebouché B; Jenabian MA; Singer J; Graziani GM; Engler K; Trottier B; Thomas R; Brouillette MJ; Routy JP
Trials; 2014 Oct; 15():390. PubMed ID: 25293882
[TBL] [Abstract][Full Text] [Related]
19. Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy.
Kaufmann GR; Furrer H; Ledergerber B; Perrin L; Opravil M; Vernazza P; Cavassini M; Bernasconi E; Rickenbach M; Hirschel B; Battegay M;
Clin Infect Dis; 2005 Aug; 41(3):361-72. PubMed ID: 16007534
[TBL] [Abstract][Full Text] [Related]
20. Individual Differences in CD4/CD8 T-Cell Ratio Trajectories and Associated Risk Profiles Modeled From Acute HIV Infection.
Paul R; Cho K; Bolzenius J; Sacdalan C; Ndhlovu LC; Trautmann L; Krebs S; Tipsuk S; Crowell TA; Suttichom D; Colby DJ; Premeaux TA; Phanuphak N; Chan P; Kroon E; Vasan S; Hsu D; Carrico A; Valcour V; Ananworanich J; Robb ML; Ake JA; Sriplienchan S; Spudich S;
Psychosom Med; 2022 Oct; 84(8):976-983. PubMed ID: 36162059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
